BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 31908303)

  • 1. Second-line therapies in advanced biliary tract cancers.
    Tella SH; Kommalapati A; Borad MJ; Mahipal A
    Lancet Oncol; 2020 Jan; 21(1):e29-e41. PubMed ID: 31908303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New developments in systemic therapy for advanced biliary tract cancer.
    Morizane C; Ueno M; Ikeda M; Okusaka T; Ishii H; Furuse J
    Jpn J Clin Oncol; 2018 Aug; 48(8):703-711. PubMed ID: 29893894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer.
    Peirce V; Paskow M; Qin L; Dadzie R; Rapoport M; Prince S; Johal S
    Target Oncol; 2023 Nov; 18(6):837-852. PubMed ID: 37751011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status of chemotherapy for the treatment of advanced biliary tract cancer.
    Sasaki T; Isayama H; Nakai Y; Koike K
    Korean J Intern Med; 2013 Sep; 28(5):515-24. PubMed ID: 24009445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimum chemotherapy for the management of advanced biliary tract cancer.
    Ghosn M; Kourie HR; El Rassy E; Chebib R; El Karak F; Hanna C; Nasr D
    World J Gastroenterol; 2015 Apr; 21(14):4121-5. PubMed ID: 25892861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic treatment options for advanced biliary tract carcinoma.
    Xie C; McGrath NA; Monge Bonilla C; Fu J
    J Gastroenterol; 2020 Oct; 55(10):944-957. PubMed ID: 32748173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma.
    Mahipal A; Tella SH; Kommalapati A; Anaya D; Kim R
    Cancer Treat Rev; 2019 Aug; 78():1-7. PubMed ID: 31255945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination versus mono-therapy as salvage treatment for advanced biliary tract cancer: A comprehensive meta-analysis of published data.
    Ying J; Chen J
    Crit Rev Oncol Hematol; 2019 Jul; 139():134-142. PubMed ID: 30979533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow.
    Rizzo A; Ricci AD; Tober N; Nigro MC; Mosca M; Palloni A; Abbati F; Frega G; DE Lorenzo S; Tavolari S; Brandi G
    Anticancer Res; 2020 Jun; 40(6):3013-3030. PubMed ID: 32487595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical Trials.
    Chiang NJ; Chen LT; Shan YS; Yeh CN; Chen MH
    Biomolecules; 2021 Jan; 11(1):. PubMed ID: 33451059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biliary tract carcinomas: from chemotherapy to targeted therapy.
    Marino D; Leone F; Cavalloni G; Cagnazzo C; Aglietta M
    Crit Rev Oncol Hematol; 2013 Feb; 85(2):136-48. PubMed ID: 22809696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted Therapy in Biliary Tract Cancers.
    Merla A; Liu KG; Rajdev L
    Curr Treat Options Oncol; 2015 Oct; 16(10):48. PubMed ID: 26266637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-line therapy in advanced biliary tract cancer: what should be the standard?
    Cereda S; Belli C; Rognone A; Mazza E; Reni M
    Crit Rev Oncol Hematol; 2013 Nov; 88(2):368-74. PubMed ID: 23786845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and emerging therapies for advanced biliary tract cancers.
    Kam AE; Masood A; Shroff RT
    Lancet Gastroenterol Hepatol; 2021 Nov; 6(11):956-969. PubMed ID: 34626563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers.
    Boilève A; Verlingue L; Hollebecque A; Boige V; Ducreux M; Malka D
    Expert Opin Investig Drugs; 2021 Apr; 30(4):401-409. PubMed ID: 33641556
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of biliary tract carcinoma over the last 30 years.
    Midorikawa Y
    Biosci Trends; 2022 Jul; 16(3):189-197. PubMed ID: 35732436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there any place for novel agents in treating biliary tract cancer?
    Perego G; Burgio V; Nozza R; Longobardo G; Bernecich M; Luciani A; Petrelli F
    Med Oncol; 2021 Feb; 38(2):19. PubMed ID: 33543377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Horizons for Precision Medicine in Biliary Tract Cancers.
    Valle JW; Lamarca A; Goyal L; Barriuso J; Zhu AX
    Cancer Discov; 2017 Sep; 7(9):943-962. PubMed ID: 28818953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging Systemic Therapies in Advanced Unresectable Biliary Tract Cancer: Review and Canadian Perspective.
    Tam VC; Ramjeesingh R; Burkes R; Yoshida EM; Doucette S; Lim HJ
    Curr Oncol; 2022 Sep; 29(10):7072-7085. PubMed ID: 36290832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging treatment strategies in hepatobiliary cancer.
    Guven DC; Yildirim HC; Chalabiyev E; Kus F; Yilmaz F; Yasar S; Akyildiz A; Aktas BY; Yalcin S; Dizdar O
    Expert Rev Anticancer Ther; 2023 Mar; 23(3):243-256. PubMed ID: 36803258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.